MIRM — Mirum Pharmaceuticals, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-07-18.
Performance
Technicals
Others in Healthcare
Measured signals that fired on MIRM
| date | signal | measured base rate |
|---|---|---|
| 2026-08-06 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-08-06 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-06 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-06-22 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-18 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-18 | Howe Jolanda SVP, GLOBAL CONTROLLER | Open-market sale | 40.0K | 100.00 | 4.0M |
| 2026-08-18 | Howe Jolanda SVP, GLOBAL CONTROLLER | Option exercise | 40.0K | 6.27 | 250.8K |
| 2026-08-11 | BJERKHOLT ERIC CHIEF FINANCIAL OFFICER | Open-market sale 10b5-1 plan | 6.0K | 99.90 | 599.5K |
| 2026-08-10 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Open-market sale 10b5-1 plan | 11.7K | 98.51 | 1.2M |
| 2026-08-10 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Open-market sale 10b5-1 plan | 6.0K | 99.25 | 597.2K |
| 2026-08-10 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Open-market sale 10b5-1 plan | 2.3K | 100.14 | 230.3K |
| 2026-08-10 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 plan | 20.0K | 2.94 | 58.7K |
| 2026-08-03 | Howe Jolanda SVP, GLOBAL CONTROLLER | Open-market sale 10b5-1 plan | 1.8K | 105.29 | 193.7K |
| 2026-07-06 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Open-market sale 10b5-1 plan | 12.1K | 121.65 | 1.5M |
| 2026-07-06 | Peetz Christopher CHIEF EXECUTIVE OFFICER | Open-market sale 10b5-1 plan | 4.2K | 122.34 | 511.5K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 709.4M | 7.7M |
| JANUS HENDERSON GROUP PLC | 641.8M | 6.9M |
| BlackRock, Inc. | 355.3M | 3.8M |
| VANGUARD CAPITAL MANAGEMENT LLC | 223.1M | 2.4M |
| FMR LLC | 181.6M | 2.0M |
| STATE STREET CORP | 179.6M | 1.9M |
| BVF INC/IL | 146.4M | 1.6M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 132.3M | 1.4M |
| EVENTIDE ASSET MANAGEMENT, LLC | 130.1M | 1.4M |
| WELLINGTON MANAGEMENT GROUP LLP | 123.3M | 1.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 4 | 2026-08-19 | 2026-08-18 | on EDGAR ↗ |
| 144 | 2026-08-18 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 4 | 2026-08-12 | 2026-08-11 | on EDGAR ↗ |
| 4 | 2026-08-11 | 2026-08-10 | on EDGAR ↗ |
| 144 | 2026-08-11 | — | on EDGAR ↗ |
| 144 | 2026-08-10 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-06 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Mirum Pharmaceuticals, Inc. (MIRM) filed form 4 · 2026-08-19 · SEC EDGAR
- Mirum Pharmaceuticals, Inc. (MIRM) filed form 144 · 2026-08-18 · SEC EDGAR
- Mirum Pharmaceuticals Stock Sinks as Widening Quarterly Loss Offsets Raised Full-Year Sales Guidance - TIKR.com · 2026-08-11 · TIKR.com
Ask the AI about MIRM
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →